Warning: Last items in stock!
Regorafenib is a kinase inhibitor indicated for the treatment of patients with:
Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti- VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
|Warnings||Don't take the drug without consulting a qualified doctor or physician.|
|Suggested use||Follow the doctor's advice|
|Delivery & Returns||10-20 days|